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Background: Folic acid supplementation reduces the risk of neural tube defects and congenital heart defects. The
biological mechanisms through which folate prevents birth defects are not well understood. We explore the use of
zebrafish as a model system to investigate the role of folate metabolism during development.
Results: We first identified zebrafish orthologs of 12 human folate metabolic genes. RT-PCR and in situ analysis
indicated maternal transcripts supply the embryo with mRNA so that the embryo has an intact folate pathway. To
perturb folate metabolism we exposed zebrafish embryos to methotrexate (MTX), a potent inhibitor of dihydrofolate
reductase (Dhfr) an essential enzyme in the folate metabolic pathway. Embryos exposed to high doses of MTX
exhibited developmental arrest prior to early segmentation. Lower doses of MTX resulted in embryos with a
shortened anterior-posterior axis and cardiac defects: linear heart tubes or incomplete cardiac looping. Inhibition of
dhfr mRNA with antisense morpholino oligonucleotides resulted in embryonic lethality. One function of the folate
pathway is to provide essential one-carbon units for dTMP synthesis, a rate-limiting step of DNA synthesis. After
24 hours of exposure to high levels of MTX, mutant embryos continue to incorporate the thymidine analog BrdU.
However, additional experiments indicate that these embryos have fewer mitotic cells, as assayed with phospho-
histone H3 antibodies, and that treated embryos have perturbed cell cycles.
Conclusions: Our studies demonstrate that human and zebrafish utilize similar one-carbon pathways. Our data
indicate that folate metabolism is essential for early zebrafish development. Zebrafish studies of the folate pathway
and its deficiencies could provide insight into the underlying etiology of human birth defects and the natural role
of folate in development.Background
Folate one-carbon metabolism (FOCM) plays an integral
role in human development and disease. Genetic variants
in folate pathway genes are associated with increased risk
for neural tube defects (NTD) (and other congenital
defects) [1], cardiovascular disease [2], cancer [3] and
cognitive decline [4]. Women taking supplemental folic
acid prior to conception significantly reduce their chance
of having an NTD affected pregnancy [5]. The mechan-
ism by which folic acid reduces the incidence of NTD’s
has not been fully elucidated.
Neural tube defects are a common congenital malfor-
mation affecting 1 in 1000 conceptuses. In humans,* Correspondence: lbrody@mail.nih.gov
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medium, provided the original work is properneural tube closure occurs by day 28 post-conception and
involves a complex co-ordination of morphogenic activ-
ities and regulatory processes. Events this early in develop-
ment are not amenable to study in humans and difficult to
observe in mammalian model organisms. The mouse is a
well-developed model organism for studying neural tube
defects and the role of folate, however the research is lim-
ited by litter size and stage at which the defects can be
studied [6]. For example, homozygous mutants in methio-
nine synthase, an enzyme in the folate pathway (Figure 1),
are embryonic lethal and are resorbed prior to E9.5 [7].
While the role of the folate pathway during development
is being investigated in the invertebrate model organisms
Drosophila [8] and C. elegans [9] , these models are evolu-
tionarily distant from vertebrates. As with the invertebrate
models, zebrafish can be studied in large numbers and are
more closely related to mammals. The mechanical andThis is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
Figure 1 Folate mediated one-carbon cycle. Folic acid (vitamin B9) is a cofactor in one-carbon metabolism, acting as a shuttle for methyl groups
that will be used in the metabolism of s-adenosyl methionine (SAM), de novo synthesis of purines and thymidylate. Dihydrofolate reductase (dhfr), an
enzyme involved in the recycling of this cofactor, reduces dihydrofolate to tetrahydrofolate (THF), thereby preparing the folate derivative for
subsequent methyl group addition. This enzyme is competitively inhibited by methotrexate (MTX), a chemotherapeutic drug with a thousand fold
higher binding affinity for dhfr then its natural substrate, dihydrofolate TYMS – thymidylate synthetase, MTHFD – methylenetetrahydrofolate
dehydrogenase, MTHFR – methylenetetrahydrofolate reductase, MS – methionine synthase, MTRR – methionine synthase reductase, MAT- Methionine
adenosyltransferase, SAHH - s-adenosyl homocysteine hydrolase, SAH – s-adenosyl homocysteine. Enzymes in red are discussed in this paper.
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fer from that found in mammals [10] but the genetic pro-
grams of notochord formation and development are
shared between fish and humans [11]. The significant
advantages of working with zebrafish (external fertilization,
large clutch size, and transparency) may render it a useful
investigative model for studying the role of folate in devel-
opment and disease.
Folate, also known as vitamin B9, is a cofactor for
enzymes involved in cellular transmethylation reactions
and de novo synthesis of purines and thymidylate [12]. In
its reduced form, the folate molecule acts a carrier of sin-
gle carbon units. The ultimate donors of the methyl
groups are serine, glycine, histidine and formate. Methy-
lated folates are cofactors in two steps during inosine syn-
thesis (the precursor of purine bases) and in the synthesis
of thymidylate (a precursor necessary for DNA synthesis).
The third major cellular reaction using folates as a co-
factor is the methionine cycle, whereby the methyl group
is added to homocysteine to form methionine. The subse-
quent product s-adenosyl-methionine is used in the syn-
thesis of neurotransmitters, methylation of phospholipids,
DNA methylation, histone methylation and mRNA cap-
ping. Folate dependent enzymes are found in the mito-
chondria, cytoplasm, and nucleus. Folate is a water-soluble
vitamin found primarily in leafy vegetables. Due to its pro-
tective effect in early pregnancy, folate fortification is man-
dated in the US with synthetic folate in the form of folic
acid added to milled grain products.
We sought to evaluate the zebrafish as a model for
studying vertebrate folate and one-carbon metabolism. We
aimed to understand the role of FOCM in early organ de-
velopment. There is little to no information on these path-
ways in fish. Using bioinformatics we have identifiedzebrafish orthologs of 12 human folate metabolic genes
and characterized their spatial and temporal expression
patterns. Chemical and genetic disruption of these path-
ways demonstrated that the folate pathway is essential for
several aspects of zebrafish development, as treated
embryos are embryonic lethal. We show cell cycle pertur-
bations as a result of defects in FOCM. We hypothesize
these defects are the result of reduced folate substrates for
thymidylate synthase, a rate-limiting enzyme in DNA syn-
thesis. Zebrafish studies of the folate pathway and its defi-
ciencies could provide insight into the underlying etiology




Orthologs of eleven enzymes and one transporter
involved in folate-one carbon metabolism were identified
in zebrafish by BLAST searches, cloned, and character-
ized (Figure 1 and Table 1). The six previously un-anno-
tated genes were sequenced and submitted to the ZFIN
nomenclature committee (mat2aa, mat2ab, mat2al,
mthfr, mthfd1a, and mthfd1b) and updated sequences
were submitted to GenBank. Expression of these genes
during development was measured via RT-PCR and
RNA in situ hybridization. Most genes identified in this
pathway appear to be ‘house keeping’ genes that are ma-
ternally loaded, present throughout early embryonic de-
velopment, and whose expression is predominantly
enriched in anterior CNS (Figure 2).
Dihydrofolate reductase (Dhfr), a key enzyme in the
conversion of dietary folate into the reduced bioactive
form that can be utilized by cells (EC 1.5.1.3), is found in
the zebrafish genome on chromosome 5. The predicted
Table 1 Folate Pathway Protein Homologies
zfin Human Protein % Identity % Similarity
mat1a NP_000420.1 84 94
mat2aa* # NP_005902.1 91 96
mat2ab* # " 89 96
mat2al* " mat1a 75/mat2a 73 nd
mat2b NP_037415.1 65 79
tyms NP_001062.1 82 91
dhfr NP_000782.1 61 76
mthfr* # NP_005948.3 79 89
mthfd1a* NP_005947.3 57 74
mthfd1b* " 77 88
mthfd1l NP_056255.2 80 89
mthfd2 NP_006627.2 80 91
mthfd2L NP_001138450.1 67 82
mtr NP_000245.2 78 89
slc25a32a NP_110407.2 66 81
slc25a32b " 70 82
nd – Not done.
* Gene name assigned as a result of this work.
# Updated sequence submitted to GenBank.
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protein (NP_000782.1) [13]. This transcript is maternally
loaded and is present throughout the first 72 hours of
development. At 24hpf the transcript is enriched in
neural tissues; alar plate midbrain region, CNS, optic tec-
tum, and optic vessels ([14], Figure 2B).Figure 2 Wild type expression data for folate pathway transcripts. A)
development indicates that genes involved in the folate pathway are gene
development. B) in situ hybridization for these 16 genes at 24 hpf shows th
tissues including tectonic and retinal staining. Specific somatic staining is se
in mat1a and mthfd1b. Embryos in lateral view.Methionine adenosyltransferases (MAT) are a family of
enzymes that catalyze the synthesis of s-adenosylmethionine
from methionine and ATP (EC 2.5.1.6). Folate is a cofactor
in the preceding reaction that generates the methionine
from homocysteine. Mat1a encodes the liver specific
forms of this enzyme, MATI and MATIII [15]. Mat2a is
expressed throughout the organism and encodes MATII.
The regulatory subunit for MATII is encoded by mat2b
[16]. Orthologs of these genes are found in zebrafish.
Mat1a is located on chromosome 13 and has 84% identity
(94% similarity) to the human protein (NP_000420.1). The
transcript for this gene is not expressed until after the
onset of gastrulation, by 24 hpf its expression is enriched
in the YSL and myotomes ([14], Figure 2). Mat2b is found
on chromosome 21 and has 65% identity (79% similarity)
to the human protein (NP_037415.1). This is a maternally
loaded transcript and is expressed throughout early zebra-
fish development. At 24 hpf, its expression is enriched in
anterior neural tissues (Figure 2). The zebrafish genome
has two paralogs of human Mat2a (NP_005902.1): Mat2aa,
with 91% identity (96% similarity) on chromosome 10 and
Mat2ab with 89% identity (96% similarity) on chromosome
5. Mat2aa is a maternally expressed gene whose expres-
sion decreases as development progresses. Mat2ab is a
maternally loaded transcript and is present throughout the
early stages of development. Both these transcripts are
enriched in myotomes and anterior neural structures at 24
hpf ([14], Figure 2). The zebrafish genome contains an-
other paralog in the mat family, which we propose to
name Mat2a-like (mat2al), located on chromosome 10.RT-PCR analysis of 11 embryonic stages within the first 72 hours of
rally maternally loaded transcripts that are expressed throughout early
at many are globally expressed with enrichment in anterior neural
en in mat1a, mat2aa, mat2ab, and mthfr. YSL staining is also observed
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identity to Mat1a, similar enough to be identified as
a methionine adenosyltransferases, but not similar enough
to be identified definitively as either one. It has a develop-
mental expression profile, via RTPCR, similar to mat1a,
but via in situ hybridization at 3 dpf we have not observed
its expression being limited to the primitive liver (data not
shown). At 1 dpf, its expression is enriched in the CNS
(Figure 2).
Mthfd1 is a cytoplasmic trifunctional enzyme that
interconverts methylene THF, methenyl THF, formyl
THF, and formate. These folates serve as substrates
for downstream reactions that synthesize thymidylate,
methionine, and inosine. The protein is partitioned into
an N-terminal bifunctional dehydrogenase and cyclohy-
drase domain (EC 1.5.1.5 and 3.5.4.9), and a C-terminal
synthetase domain (EC 6.3.4.3). The mitochondrial pro-
tein, Mthfd1L retains a functional synthetase domain.
However, while the N-terminal domain is present, muta-
tions in critical residues results in the predicted loss of
these enzymatic functions [17]. The mitochondrial de-
hydrogenase and cyclohydrase reactions are performed by
the proteins Mthfd2 and Mthfd2L. Mthfd2 is only found
in transformed mammalian cells and embryonic or nondif-
ferentiated tissues [18] and is essential during embryonic
development [19]. Mthfd2L has recently been shown to be
the active mitochondrial enzyme in adult tissues [20].
Orthologs of all these human proteins are found in zebra-
fish. Two paralogs of Mthfd1 (NP_005947.3) are found in
zebrafish: mthfd1a has 57% identity (74% similarity) to the
human protein and is located on chromosome 20,
mthfd1b has 77% identity (88% similarity) and is located
on chromosome 17. Mthfd1b is the likely true ortholog of
human Mthfd1 as it retains the conserved amino acids in
the catalytic domains of this trifunctional enzyme. However,
Mthfd1a has a predicted mitochondrial leader sequence
(p=0.9736, [21]) and has mutations in conserved catalytic
residues in the synthetase domain. This transcript is dynam-
ically regulated within the first 72 hpf. Mthfd1b is expressed
throughout early development. At 24 hpf, both transcripts
are enriched in the CNS, with mthfd1b also expressed
in the YSL ([14], Figure 2). An ortholog of Mthfd1L
(NP_056255.2) can be identified in zebrafish, on
chromosome 20, with 81% identity (89% similarity) to
the synthetase domain. While the zebrafish transcript is
predicted to encode a mitochondrial leader sequence, the
dehydrogenase/cyclohydrase domain has only 44% identity
to the human protein. This transcript is not maternally
expressed and is dynamically regulated throughout early
development. Its expression is not spatially restricted at 24
hpf (Figure 2B). One ortholog of Mthfd2 (NP_006627.2) is
found on chromosome 5 in zebrafish with 80% identity
(92% similarity). An Mthfd2L ortholog is located on
chromosome on 8, with 67% identity (82% similarity).Both of these transcripts are dynamically expressed
throughout the first 72 hours of development, with ex-
pression at 24 hpf being enriched in the CNS (Figure 2).
Methylenetetrahydrofolate reductase (Mthfr, EC 1.5.1.20)
catalyzes the irreversible reduction of the one carbon donor
group on folate to 5-methyl-tetrahydrofolate. This form
of folate is the carbon donor in the conversion of homo-
cysteine to methionine. An ortholog of the human protein
(NP_ 005948.3) is found in the zebrafish genome on
chromosome 8 with 79% identity (89% similarity)
(NP_001121727.1). This is also a maternally loaded
transcript and is present throughout the early stages of
development. At 24 hpf its expression is also enriched
in the CNS and myotomes (Figure 2B).
Methionine synthase (Ms, EC 2.1.1.13), encoded
by the gene mtr, is the enzyme that catalyzes the
conversion of homocysteine to methionine, using 5-
methyl-tetrahydrofolate as the methyl group donor
and the vitamin cofactor cobalamin (vitamin B12).
This enzyme sits at the intersection of the folate pathway
and the methionine cycle. Zebrafish has one ortholog of
this protein (NP_00245.2) on chromosome 12 with 77%
identity (88% similarity). The transcript is maternally
loaded and present throughout the first three days of em-
bryonic development. At 24hpf its expression is enriched
in the CNS ([14], Figure 2B).
Thymidylate synthetase (Tyms, EC 2.1.1.45) is an enzyme
involved in a rate-limiting step of DNA synthesis: the
methylation of dUMP to dTMP. This reaction uses a folate
cofactor as the one carbon donor. An ortholog of the
human protein (NP_001062.1) is found in the zebrafish ge-
nome on chromosome 7 with 82% identity (91% similarity).
This is also a maternally loaded transcript and is present
throughout the early stages of development. At 24 hpf its
expression is also enriched in the CNS ([14], Figure 2B).
We also investigated the transport protein, Slc25a32
(MFTC), a mitochondrial membrane protein that trans-
ports folate into the mitochondrion [22]. Two paralogs of
Slc25a32 (NP_110407.2) are found in zebrafish. Slc25a32a
is located on chromosome 19 and has 66% identity (81%
similarity) to the human protein. This transcript is also
maternally expressed and is present throughout early de-
velopment. At 24 hpf it is expression is not spatially
restricted (Figure 2B). Slc25a32b is located on chromo-
some 16, has 70% identity (82% similarity) to the human
protein, and is expressed throughout early embryonic de-
velopment. Its expression is enriched in anterior neural
tissues at 24 hpf (Figure 2B).
Dhfr Inhibition
In order to investigate the role of the folate pathway in
early zebrafish development, we inhibited Dhfr by using
either the chemotherapeutic drug methotrexate or anti-
sense morpholino oligonucleotides.
Figure 3 Methotrexate treatment confers dose-dependent
developmental delay. A) Treatment with lower concentrations of
MTX causes shortening of the anterior-posterior axis and heart
defects, while higher doses result in embryonic lethality prior to
somitogenesis. B) Defects evident at 2 dpf in embryos treated with
200 μM methotrexate are alleviated by treatment with 10 mM
Folinic Acid (FA). Embryos in lateral view.
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inhibiting Dhfr [23]. Zebrafish embryos were treated with
varying concentrations of methotrexate, within 30 minutes
of fertilization. At the highest concentration of methotrex-
ate tested, 600 μM, most embryos died prior to 1 dpf. The
few surviving embryos were morphologically abnormal,
arresting between epiboly and early somitogenesis. As the
concentration of methotrexate decreased, the severity of
the phenotype diminished, but even the lowest concentra-
tion of methotrexate tested, 100 μM, resulted in embryonic
lethality by 5 dpf. These fish were characterized by ventral
edema, dorsal curvature, shortened A/P axis, and defective
heart morphology. Embryos treated with 200 μM metho-
trexate had a mild delay at tailbud stage. By 1 dpf, these
embryos displayed necrotic heads and tails with dorsal
curvature and a shortened A/P axis (Figure 3A). Embryos
developed ventral edema and heart defects that ultimately
resulted in embryonic lethality by day 5. The majority of
embryos treated with 400 μM methotrexate resulted in
embryonic lethality prior to somitogenesis (Figure 3A). A
minority of embryos developed past early somitogenesis
but had severely shortened A/P axis with necrosis through-
out the embryo and cardiac defects.
Folinic acid, a folate derivative that can enter the folate
metabolic pathway without the enzymatic function of
Dhfr, is used during chemotherapy to ameliorate the
toxic effects of methotrexate [24]. Embryos pre-treated
with folinic acid in addition to 200 μM methotrexate
showed fewer severe defects at 2 dpf: less edema, fewer
embryos with dorsal curvature and a decrease in cardiac
defects (Figure 3B). However, this treatment was unable
to completely rescue methotrexate treatment as the
embryos died by 5 dpf.
We confirmed the specificity of the observed defects
being due to abrogation of the folate pathway by using
morpholinos against dhfr. The same spectrum of defects
was observed when embryos were treated with either
translation or splice blocking morpholinos. Microinjection
of 0.2 pmol of translation blocking morpholino [13]
resulted in over 50% of embryos displaying the severe de-
fect of developmental arrest after tailbud stage (Figure 4A).
Less than 10% of embryos treated with 0.75 pmol of splice
blocking morpholino, designed to bind the intron 3- exon
4 splicing boundary, exhibited this severe early phenotype
(Figure 4A). RT-PCR analysis of dhfr in treated embryos
showed laddering bands characteristic of splicing defects
(Figure 4B) [25]. Sequencing results from these aberrant
bands demonstrated that these bands were the result of
skipping either exons 3 and 4 or just exon 4 and resulted in
a pre-mature termination codon (data not shown). With
this treatment, most embryos exhibited shortened anterior-
posterior axis, ventral edema, dorsal curvature, cardiac
defects, and a noticeable decrease in their touch response,
culminating in embryonic lethality. In contrast, injectionof 0.2 pmol of the 5 bp mismatch (MM) translation block-
ing morpholino control resulted in 90% viability at 5 dpf.
Co-injection with a morpholino targeting p53, which
blocks nonspecific morpholino induced apoptosis, resulted
in similar phenotypes as the dhfr ATG morpholino alone
(data not shown).
Differentiation and tissue specification
The developmental defects observed in fish with disrup-
tions in one carbon metabolism could be due to failure
of differentiation. To test this we performed in situ ana-
lysis of markers of primarily neuro-ectodermal tissues.
Figure 4 dhfr morpholino injection phenocopies methotrexate treatment defects. A) Epiboly in dhfr ATG morphants is significantly delayed
at 10 hpf as compared to controls. By 28 hpf severe dhfr ATG morphants are developmentally arrested with a failure to complete epiboly.
Intron-exon splice morphants complete epiboly but exhibit shortened anterior-posterior axis and heart defects. Embryos in lateral view. B)
Diagram of dhfr mRNA, i3e4 splice blocking morpholino, and primers used for RT-PCR (sequences supplied in Additional file 2: Table S2). cDNA
generated from embryos at 6 hpf demonstrate splicing defects in dhfr transcripts in embryos treated with morpholino (mut). Control injected
embryos (con) have only expected band sizes.
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abnormal, embryos treated with 400 μM methotrexate
were able to specify developmentally appropriate tissues
(Figure 5). The enveloping layer (krt18) develops and
migrates, despite delays and defects in blastopore clos-
ure. Treated embryos form a dorsal shield with involut-
ing cells (as indicated by gsc and foxa2 in situ
hybridization), which gives rise to neural plate and
neural tube structures, respectively, by bud stage. ntl
indicates margin cells during shield stage and notochord
at bud stage. By 24 hpf, ntl staining indicates an abnor-
mal shortened wavy notochord. This observation is sup-
ported by somite staining with myoD. foxA2 and crestin,
a marker of neural crest, also showed an abnormal stain-
ing pattern, but demonstrates that tissues are specified.
Finally, the hatching gland, hgg1, indicates the anterior
most structure of the zebrafish is also specified. The endo-
thelial marker kdrl was appropriately specified, as were the
anterior neural markers wnt1, sox3, and pax6a (data not
shown). While tissues queried were all appropriately speci-
fied, the notochord is abnormal and could indicate a defect
in the overlying neural tube.Cell cycle aspects of folate pathway perturbations
Embryos treated with methotrexate are phenotypically ab-
normal but tissues are normally specified. We hypothesized
the defect is in the number of cells in the embryo, due to
defects and delays in the cell cycle in response toreduced folate substrate for the enzyme thymidylate
synthetase.
Methotrexate treated embryos were assessed in their
ability to incorporate the thymidine analog, BrdU, into
their DNA. Embryos treated with methotrexate readily
incorporated BrdU into their DNA, demonstrating compe-
tence in S-phase (Figure 6A). This assay is not sensitive
enough to detect an increase in the number of cells in S-
phase. In order to assess cells in M-phase, we performed
immunocytochemistry using an antibody to phospho-
histone H3, a mitosis specific marker. Embryos treated
with methotrexate showed a decreased number of phos-
pho-histone H3 positive cells (Figure 6B). These data
were supported by DNA content analysis via flow cyto-
metry. Embryos treated with 200 μM methotrexate for
24 hours showed an increased proportion of cells in S-phase
with a concomitant decrease in cells in M-phase (Figure 6C).
This defect was not observed in embryos pre-treated with
folinic acid. Embryos treated with 400 μM methotrexate
demonstrated a severe skewing of cells to the 2 N and
sub-2 N DNA content. This sub-2 N DNA peak suggests
an increase in apoptotic cells. To test this possibility we
performed TUNEL assays on treated and untreated
embryos. Embryos treated with methotrexate demon-
strated an increase in apoptotic cells (data not shown).
Methotrexate treatment causes S-phase delay, a decrease
in the number of mitotic cells, and an increase in
apoptosis, resulting in an overall decrease in the num-
ber of cells within the developing embryo.
Figure 5 Methotrexate–treated embryos maintain expression of appropriate developmental markers. Expression patterns were visualized
via whole-mount in situ hybridization in embryos treated with 400 μM MTX and fixed at shield stage (A-H), tailbud (I-P), and 24 hpf (Q-W’). While
MTX-treated embryos at 24hpf are clearly delayed with respect to normal development, they do express appropriate developmental markers: krt18
–enveloping layer, gsc – involuting cells and neural plate, ntl – blastomere margin, notochord and dorsal organizer, foxA2 – involuting cells and
neural plate, crestin – neural crest, myoD – paraxial mesoderm, hgg- hatching gland (anterior most structure), ngn – CNS. (A-J) Animal view, dorsal
to the right. (K-P) Lateral view with dorsal view inset. (Q, R, R’, T, V, W, X, X’) Dorsal view. (S, U, V’) Lateral view. (T’) ventral view.
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Our aim was to identify and characterize components of
the folate pathway and to interrogate its role in early
zebrafish development. Twelve genes involved in folate
metabolism were identified by BLAST searches, cloned,
and their expression profiles studied by RT-PCR andFigure 6 Abnormal cell cycle properties of methotrexate treated emb
exposure, embryos are capable of incorporating BrdU via DNA synthe
H3 shows a decreased number of mitotic cells in methotrexate treated em
embryos do not display WT cell cycling profiles, with a probable S-phase ac
cell cycle profiles. Lateral views of 24 hpf embryos. Scale bar: 100 μm.RNA in situ hybridization. We also assessed the impact of
inhibiting the folate pathway in the developing zebrafish by
treatment with the folate antagonist, methotrexate, and by
microinjection of antisense morpholino oligonucleotides
designed to disrupt Dhfr expression. Inhibition of the folate
pathway caused perturbations in the cell cycle, whichryos A) After 24 hours of 200 μM or 400 μM methotrexate
sis. B) Immunohistochemistry for the mitotic marker phospho-histone
bryos. C) However, FACS analysis clearly indicates methotrexate treated
cumulation. Co-treatment with folinic acid and methotrexate restores
Lee et al. BMC Developmental Biology 2012, 12:12 Page 8 of 11
http://www.biomedcentral.com/1471-213X/12/12resulted in embryonic lethality. While it is not surprising
that this pathway is essential for development, the mech-
anism through which this inhibition acts had not been
explored. We propose the primary defect in these fish is
the lack of folate substrates for Tyms, a rate-limiting step
in DNA synthesis, which results in the lack of dTTP pools
for DNA synthesis. However, it is also possibile that other
methylation reactions, requiring s-adenosylmethionine (a
downstream product of folate one- carbon pathway), also
play a role in the defects we observed.
We set out to identify and clone 12 orthologs of folate
genes in humans. We identified 16 orthologs and paralogs,
presumably due to the partial genome duplication that oc-
curred in teleosts [26]. The presence of paralogs can com-
plicate studies that try to establish gene function by
looking at single gene knock-out (down) phenotypes. One
set of duplicated genes we identified was the mats: mat1a
and mat2a. Mat1a encodes the liver specific isoform of
the enzyme. Mat2a encodes the globally expressed iso-
form. Zebrafish has four mat genes. One is clearly mat1a,
with 77% identity to the human protein and liver expres-
sion at 3 dpf (data not shown). Two genes, mat2aa and
mat2ab, appear to be paralogs of human mat2a, with 80%
identity to the human protein and without liver restricted
expression. The fourth gene, mat2al, has a temporal ex-
pression pattern similar to mat1a, but without the liver
restricted expression, similar to the mat2as, and relatively
low (75% and 73%) identity to the human Mat1a and
Mat2a proteins, respectively. This highlights one of the
challenges of transferring pathways between species.
Queried members of the folate pathway are generally
maternally loaded and ubiquitously expressed (with enrich-
ment in anterior neural tissues), consistent with the idea
that they are house-keeping genes involved in an essential
cellular process. Inhibition of the pathway with either the
folate antagonist methotrexate or by using morpholinos
targeting dhfr results in early embryonic lethality. Further
study of methotrexate treated embryos indicates defects in
the cell cycle, specifically S-phase accumulation and
increased apoptosis. By visual morphological criteria and
in situ analysis embryos have a normal developmental pro-
gram through bud stage. Between 12 hpf and 24 hpf devel-
opment defects arise, as >80% of embryos treated with
400 μM methotrexate die overnight and the surviving
embryos are anatomically abnormal. Neural cells condense
to form the neural plate around the 2 somites stage
(11 hpf ) [10]. Most embryos treated with methotrex-
ate do not survive treatment to be queried specifically for
neural tube defects. Despite decreased cell numbers due to
S-phase delay and concomitant decreased mitosis, the de-
velopmental program proceeds and appropriate tissues are
specified, although the anterior-posterior axis is severely
shortened and the notochord undulates. Convergent/
extension defects, resulting in embryos with a shortenedA-P axis, are observed in zebrafish expressing rare variants
of VANGL1 that are associated with neural tube defects in
humans [27].
One limitation of using zebrafish as a model system
for understanding genetic and environmental etiologies
of neural tube defects is that the mechanics of zebrafish
neurulation differs from that of human and mouse.
Zebrafish form a neural plate, which then progresses
through a neural keel stage, to a solid neural rod which
then cavitates to a neural tube [10]. Zebrafish do not
form a neural tube via the bending of the neural plate
and fusing of opposing sides. In humans and mice, the
failure of these tissues to fuse presents as a neural tube
defect, whether in its lethal form of anencephaly or the
milder state of spina bifida. However, many of the mo-
lecular and genetic aspects of neural tube formation are
genetically conserved between humans and fish [28].
The essential requirement for the folate pathway has
been documented in other model organisms ranging
from yeast to mice. Of the genes we studied, only dfr1
(dhfr) and cdc21 (tyms) are essential in budding yeast.
Mtr −/− mice are embryonic lethal prior to day E9.5 [7].
Mthfd1 −/− mice also are embryonic lethal [29] as are
Mthfd2 −/− mice, by day E13.5, and can be distinguished
by their smaller size and pale livers [19]. In contrast
Mthfr −/− knock out mice are viable, although with
reduced viability, decreased body size, and cerebellar
pathology [30]. A small number of reports have investi-
gated folate pathway genes and mutants in zebrafish.
Sun et al. [13] reported cardiac defects in zebrafish dhfr
morphants. Similar cardiac defects were also reported
for zebrafish embryos treated with methotrexate, as well
as decreased expression of the cardiac markers (hand2,
mef2a, and mef2b) [31]. Neither study reports the early
severe defects we observed nor do they interrogate cell
cycle properties of affected embryos. Zebrafish tyms
mutants were identified in screens looking for genes es-
sential for embryonic [32] or defective in retinal devel-
opment [33]. Another zebrafish mutant with ocular
defects has been identified as gart, one of two enzymes
involved in purine metabolism that uses folate as a co-
factor [34]. Our identification and characterization of
major components of the folate pathway in zebrafish
increases the utility of this model organism in studying
the role of folate in normal development and disease.
Conclusion
We provide the first in depth characterization of the folate
pathway in zebrafish, by reporting the expression patterns
of 16 genes, of which we name 6 genes in ZFIN and pro-
vide additional sequence information for 3 genes. We ex-
pand upon earlier studies that implicated Dhfr in cardiac
development by identifying an earlier defect in zebrafish.
Folate starved embryos start to show defects prior to
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phase, caused by decreased pools of thymidylate and
consequently dTTP, which in turn leads a lengthened
cell cycle. As each round of division takes longer, fewer
total cells are available in which to form an embryo. We
also observed an increase in apoptosis, which we
propose to be a consequence of and in response to
extended delays in S-phase. Despite the decreased num-
ber of cells and decreased size of the entire organism,
mutant embryos are able to appropriately specify the
neuro-ectodermal and mesodermal tissues that were
queried. The typical consequence of folate deficiency is
megaloblastic anemia, an enlargement of red blood
cells, due to the failure of cellular division of erythrocyte
precursors. Our data support the idea that in rapidly
dividing hematopoietic or embryonic cells, DNA syn-
thesis is susceptible before purine synthesis and other
cellular methylation reactions. Low folate status and
hyperhomocysteinemia have been implicated as poten-
tially reversible risk factors for cognitive decline and
cardiovascular disease. Our work establishes zebrafish
as a model system for studying the folate pathway and
demonstrates that zebrafish can serve as a model organ-
ism for studying the role of folate in development in
order to understand the genetic and environmental eti-
ology underlying some neural tube and congenital heart
defects.Methods
Zebrafish care
The zebrafish, TAB-5 strain (ZIRC, Eugene, OR), were bred
and maintained at 28.5°C as described [35]. Animals were
staged by hours post-fertilization (hpf) and on morpho-
logical criteria. Embryos were treated with Methotrexate
USP (GeneraMedix, Liberty Corner, NJ) and/or Leucovorin
USP (folinic acid) (Bedford Laboratories, Bedford, OH)
within 30 minutes of fertilization in 1X E3. We treated
embryos with 5 orders of magnitude more than the min-
imal chemotherapeutic dose of methotrexate. We used 14C
labeled methotrexate to measure intra-embryonic uptake
of the drug. These data suggest that only small amounts of
drug permeate the chorion into the embryo (data not
shown). Embryos were injected with up to 4 nL of diluted
morpholino (Genetools LLC, Philomath, OR) (as deter-
mined by drop size in oil) prior to 8-cell stage. Unfertilized
embryos were removed between 4–6 hpf and media was
changed at 2 dpf. Experimental protocols were reviewed
and approved by the NHGRI Animal Use and Care Com-
mittee. Morpholino sequences: tp53 GCGCCATTGCTTT
GCAAGAATTG [36], dhfr ATG 5’ ACGGTCTCGCCTT
CTTCCCGCCAAG 3’ [13], dhfr.i3e4 5’ TGTCCTGTGGA
GTGACAGAAAATAA 3’, dhfr.MM 5’ACcGTCTCGgCTT
gTTCgCGCCgAAG 3’ (mismatches in lower case).Cloning
Orthologs were identified by TBLASTN of the human
protein sequence to the zebrafish genome (Ensembl v7)
and/or cDNAs. Primers to predicted transcripts were
designed to amplify the 5’UTR and CDS. RNA was iso-
lated from 24 hpf embryos using RNA STAT-60 (Amsbio,
Abingdon, UK) and transcribed to cDNA (Superscript III,
Invitrogen, Carlsbad, CA). Transcripts were amplified
(Hotstar Taq, Qiagen, Valencia, CA), cloned into pCRII
(Invitrogen, Carlsbad, CA), and sequenced. GenBank
accession numbers: JN848834 (mat2aa), JN848835
(mat2ab), JN848836 (mthfr).
RT-PCR
RNA was isolated from staged embryos (4 cell through 72
hpf) using RNA STAT-60 (Amsbio, Abingdon, UK) or TRI
reagent LS (Sigma-Aldrich, St. Louis, MO). 1 μg of total
RNA was transcribed into cDNA (Superscript III SuperMix,
Invitrogen, Carlsbad, CA). Primers for RT-PCR were
designed to yield 400–600 bp products, biased to the 3’ end
of the transcript, and spanned at least one intron - exon
boundary (Additional file 1: Table S1). Multiple overlapping
sets of primers were designed to the dhfr transcript to query
the efficacy of morpholino induced knock-down (Additional
file 2: Table S2). Aberrant splice products were TOPO-TA
cloned (Invitrogen, Carlsbad, CA) and sequenced.
In situ hybridization
In situ probes were designed to be ~500 bp and biased
to the 3’UTR. Hybridizations were performed essentially
as described [37].
FACS
Embryos were treated with 400 μM methotrexate for
24 hours. 20–40 embryos were processed in duplicate.
After treatment, embryos were briefly rinsed in calcium-
free Ringers solution (116 mM NaCl, 2.9 mM KCl, 5 mM
HEPES pH 7.2), pestled 20 times in calcium-free Ringers,
and then passed through 40 μM filter (BD Falcon 352340),
rinsed once and resuspended in DNA staining buffer
(100 mM Tris pH 7.5, 154 mM NaCl, 1 mM CaCl,
0.5 mM MgCl, 0.2% BSA, 0.1% Nonidet P-40, 250ug/mL
Rnase, 20ug/mL propidium iodide) [38]. FACS analysis
was performed on FACSCalibur (BD Biosciences) and data
analyzed in FlowJo (Ashland, OR).
BrdU and phospho-histone H3 Assays
Phosphohistone-H3 immunochemistry was performed as
described [39]. BrdU incorporation was assayed essen-
tially as described [40] with the following modifications:
fixed embryos were permeabilized with methanol and
treated with 4 M HCl for 20 minutes. Primary mouse
anit-BrdU antibody (clone II5B, Santa Cruz) was used at
a 1:250 dilution and secondary AP-conjugated donkey
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phatase was developed with NBT/BCIP solution (Roche,
Basel, Switzerland).
Additional files
Additional file 1: Table S1. Primers for in situ and RTPCR of folate
pathway genes.
Additional file 2: Table S2. Primers sequences for dhfr RTPCR.
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